Corrigendum to “OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT” [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S3-S4]

The authors regret that some author affiliations were incorrect. Please find below the correct author list and affiliations. Enrique M. Ocio1, Aurore Perrot2, Pierre Bories3, Jesús F. San-Miguel4, Igor W. Blau5, Lionel Karlin6, Joaquín Martínez-López7, Wolfram Pönisch8, Sara Bringhen9, Magda Marcatti10, María-Victoria Mateos11, Paula Rodríguez-Otero4, Nadia LeRoux12, Yvonne Dong13, Sandrine Macé12, Thomas Fitzmaurice14, Philippe Moreau15 1University of Cantabria, Santander, Spain 2CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d'Hématologie, Toulouse, France 3Toulouse University Institute of Cancer-Oncopole, Toulouse, France 4Clínica Universidad de Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain 5Medical Clinic, Charité University Medicine Berlin, Berlin, Germany 6Service d'Hématologie Clinique, Centre Hospitalier Lyon Sud, Pierre-Bénite, France 7Departamento de Hematología, Hospital 12 de Octubre, Complutense University, CNIO, Madrid, Spain 8University of Leipzig, Leipzig, Germany 9Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy 10Vita-Salute San Raffaele University, Milan, Italy 11Institute of Cancer Molecular and Cellular Biology, University Hospital of Salamanca, Salamanca, Spain 12Sanofi, Vitry-sur-Seine, France 13Sanofi, R&D, Beijing, China 14Sanofi, Cambridge, MA, USA 15University Hospital of Nantes, Nantes, France The authors would like to apologise for any inconvenience caused. DOI of original article: 10.1016/S2152-2650(21)02079-6 Correspondence author. Dr. Enrique M. Ocio, University of Cantabria, Santander, Spain [email protected]